<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03273907</url>
  </required_header>
  <id_info>
    <org_study_id>GLD122c-C001</org_study_id>
    <nct_id>NCT03273907</nct_id>
  </id_info>
  <brief_title>Post Approval Study of the CyPass System</brief_title>
  <official_title>Post Approval Study of the CyPass System in Patients With Primary Open Angle Glaucoma Undergoing Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that the rate of clinically relevant&#xD;
      complications associated with CyPass Micro-Stent placement and stability using the CyPass&#xD;
      241-S applier, as determined at 36 months in the postmarket setting, is less than the&#xD;
      pre-specified performance target, which is based on experience with the CyPass Model E&#xD;
      applier in the COMPASS (TMI-09-01) Trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each subject's expected participation in the study is up to 37.5 months which includes up to&#xD;
      42 days between the screening and surgery visits, and 36 months of post-surgery follow-up.&#xD;
      Only one eye per subject will be implanted.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 12, 2017</start_date>
  <completion_date type="Actual">August 31, 2021</completion_date>
  <primary_completion_date type="Actual">August 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of clinically relevant complications associated with CyPass Micro-Stent placement and stability as determined at Month 36</measure>
    <time_frame>Month 36 postoperative</time_frame>
    <description>Clinically relevant complications related to the device, as specified in the protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in intraocular pressure (IOP) from baseline at Month 36</measure>
    <time_frame>Month 36 postoperative</time_frame>
    <description>IOP assessed by Goldman tonometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with IOP reduction ≥ 20% from baseline while using the same or fewer topical ocular hypotensive medications at Month 36</measure>
    <time_frame>Month 36 postoperative</time_frame>
    <description>IOP assessed by Goldman tonometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who are not using ocular hypotensive medication with IOP ≥ 6 mmHg and ≤ 18 mmHg at Month 36</measure>
    <time_frame>Month 36 postoperative</time_frame>
    <description>IOP assessed by Goldman tonometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of occurrence of sight-threatening adverse events at Month 36</measure>
    <time_frame>Month 36 postoperative</time_frame>
    <description>Sight-threatening adverse events, as specified in the protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ocular secondary surgical interventions (SSI) at Month 36</measure>
    <time_frame>Month 36 postoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ocular SSIs associated with CyPass placement and stability at Month 36</measure>
    <time_frame>Month 36 postoperative</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Primary Open-angle Glaucoma</condition>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>CyPass System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CyPass Micro-Stent implanted with CyPass 241-S applier in the angle of the eye during cataract surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CyPass Micro-Stent implanted with CyPass 241-S applier</intervention_name>
    <description>CyPass System (Model 241-S) consists of the CyPass Micro-Stent contained in a loading device (loader) and the CyPass applier.The CyPass Micro-Stent is an implantable medical device intended for long term use.</description>
    <arm_group_label>CyPass System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to understand the requirements of the study and willing to follow study&#xD;
             instructions, provide written informed consent, and agree to comply with all study&#xD;
             requirements, including the required study follow-up visits&#xD;
&#xD;
          -  Diagnosis of primary open angle glaucoma (POAG)&#xD;
&#xD;
          -  Medicated IOP of ≥10 millimeters mercury (mmHg) and ≤25 mmHg, or an unmedicated IOP of&#xD;
             ≥21 mmHg and ≤33 mmHg&#xD;
&#xD;
          -  An operable age-related cataract eligible for phacoemulsification&#xD;
&#xD;
          -  Visual acuity as specified in the protocol&#xD;
&#xD;
          -  Other protocol-specified inclusion criteria may apply.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to complete a visual field test prior to surgery&#xD;
&#xD;
          -  Use of ocular hypotensive medication/s, as specified in the protocol&#xD;
&#xD;
          -  Diagnosis of glaucoma other than POAG, as specified in the protocol&#xD;
&#xD;
          -  Other medical conditions, as specified in the protocol&#xD;
&#xD;
          -  Proliferative diabetic retinopathy&#xD;
&#xD;
          -  Previous surgery for retinal detachment&#xD;
&#xD;
          -  Previous corneal surgery&#xD;
&#xD;
          -  Wet age-related macular degeneration&#xD;
&#xD;
          -  Poor vision in the non-study eye not due to cataract&#xD;
&#xD;
          -  Significant ocular inflammation or infection within 30 days of screening visit&#xD;
&#xD;
          -  Uncontrolled systemic diseases that may put the subject's health at risk and/or&#xD;
             prevent the subject from completing all study visits&#xD;
&#xD;
          -  Women who are pregnant or nursing&#xD;
&#xD;
          -  Other protocol-specified exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sr. Clinical Trial Lead, Surgical</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <zip>32405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Garden City</city>
        <state>Kansas</state>
        <zip>67846</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Fraser</city>
        <state>Michigan</state>
        <zip>48026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investivative Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Vineland</city>
        <state>New Jersey</state>
        <zip>08361</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Bala-Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Chambersburg</city>
        <state>Pennsylvania</state>
        <zip>17201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004-3012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Kenosha</city>
        <state>Wisconsin</state>
        <zip>53142</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Racine</city>
        <state>Wisconsin</state>
        <zip>53405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 5, 2017</study_first_submitted>
  <study_first_submitted_qc>September 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2017</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CyPass Micro-Stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

